Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × Melphalan × Clear all

NCT00019760 2023-10-31

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Colonic Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Genetic Diseases, Inborn

NCT02415036 2022-10-17

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Phase 2 Terminated

17 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

56 enrolled

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT00019786 2012-03-23

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

Phase 2 Completed

67 enrolled

EndocrineGastrointestinal

Colonic Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Liver Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine